Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27216306 | 0.95 | TSHR (0.41) | TSHRALDH1A1THRBPGRADRA2A | |
| SCHEMBL14873 | 0.94 | TSHR (0.44) | TSHRALDH1A1THRBPGRADRA2A | |
| SCHEMBL28273631 | 0.94 | TSHR (0.44) | TSHRALDH1A1THRBPGRADRA2A | |
| Ammonia Solution, Strong SCHEMBL28263372 | 0.93 | TSHR (0.42) | TSHRALDH1A1THRBPGRADRA2A | |
| Hydrochloric Acid SCHEMBL9258461 | 0.93 | TSHR (0.42) | TSHRALDH1A1THRBPGRADRA2A | |
| Isopropyl Alcohol SCHEMBL20480785 | 0.91 | TSHR (0.41) | TSHRALDH1A1THRB | |
| Chloromethane SCHEMBL1128070 | 0.91 | TSHR (0.41) | TSHRALDH1A1THRB | |
| Boric Acid SCHEMBL8763863 | 0.89 | TSHR (0.40) | TSHRALDH1A1THRB | |
| SCHEMBL8106923 | 0.89 | TSHR (0.40) | TSHRALDH1A1THRB | |
| Acrylic Acid SCHEMBL7775516 | 0.88 | TSHR (0.37) | TSHRALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4652443-A | Slow-release composite and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1987-03-24 | — | — | US | claimed |
| EP-0130409-A2 | Slow-release composite and process for producing the same | Takeda Chemical Industries, Ltd. (JP) | 1985-01-09 | — | — | EP | claimed |
| CN-108290990-A | Binding property polymer and medical adhesive adhesive preparation | 帝国制药株式会社 | 2018-07-17 | — | — | CN | disclosed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9115168-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-3 | NEURMEDIX, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9102702-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | NEURMEDIX INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8569275-B2 | Steroids having 7-oxgen and 17-heteroaryl substitution | Harbor Therapeutics, Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| CN-101688145-B | Functional fluid | CHIYODA CHEMICAL CO LTD | 2013-03-27 | — | — | CN | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-4800085-A | Slow-release composite and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1989-01-24 | — | — | US | disclosed |
| US-4652443-A | Slow-release composite and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1987-03-24 | — | — | US | disclosed |
| EP-0130409-A2 | Slow-release composite and process for producing the same | Takeda Chemical Industries, Ltd. (JP) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | TSHR 2359/4885ALDH1A1 2419/4885THRB 1652/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | TSHR 1774/4885ALDH1A1 1150/4885THRB 1608/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | TSHR 3015/4885ALDH1A1 322/4885THRB 1300/4885 |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | HSD3B1, HSD3B2, HSD17B13 | TSHR 2793/4885ALDH1A1 413/4885THRB 1023/4885 |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | HSD3B1, HSD3B2, HSD17B13 | TSHR 2764/4885ALDH1A1 414/4885THRB 1066/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | TSHR 937/4885ALDH1A1 1204/4885THRB 387/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | TSHR 2231/4885ALDH1A1 800/4885THRB 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.